Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

103 clinical studies listed.

Filters:

Prostatic Neoplasms

Tundra lists 103 Prostatic Neoplasms clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

COMPLETED

NCT06242119

Clinical Application of the J-PET Scanner Prototype

Positron emission tomography (PET), an advanced diagnostic imaging technique, exploits the annihilation of positrons (e+) to delineate pathological alterations within diseased tissues. Integral to PET scanners are detector systems that transform gamma photons into fluorescent photons, thereby gleaning insights into the energy, time, and spatial distribution of gamma photons emanating from positron-emitting radiopharmaceuticals. Conventional PET scanners, bear a significant financial burden primarily due to their reliance on LSO (lutetium oxyorthosilicate) or LYSO (lutetium yttrium oxyorthosilicate) scintillation crystals. The exorbitant cost and limited availability of these crystal scintillators impede the widespread adoption of PET scanners. In a departure from conventional PET technology, the prototype J-PET scanner employed in this trial employs plastic scintillators, characterized by unique physical properties. This prototype is further equipped with bespoke software enabling three-photon imaging based on the annihilation of ortho-positronium (o-Ps) generated within diseased tissue. This study delves into the clinical applicability of PET scanners employing plastic scintillators, particularly investigating the feasibility of PET imaging using plastic scintillators where gamma quanta interact by mechanisms other than the photoelectric effect. Furthermore, this study endeavors to contemporaneously acquire and analyze data related to the lifetime of ortho-positronium (o-P) atoms emanating from routine radiopharmaceuticals. Additionally, it seeks to validate the utilization of a novel diagnostic indicator, termed the \"positron biomarker,\" through a prospective study, comparing its efficacy to conventional diagnostic PET scanning methodologies.

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-20

Prostate Cancer
Prostatic Hyperplasia
Prostatic Neoplasms
+3
RECRUITING

NCT05616650

Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor

Background: The current standard treatment of prostate cancer is either surgery or radiation. Typically, this includes either the removal or radiation of the whole prostate gland. Many people now seek out focal therapy options to decrease the side effects of treatment. Until now, several forms of physical destruction with heat (thermal ablation), cold (cryotherapy), sound waves (HIFU), laser (FLA), and electrical energy (IRE). A new type of radiation (SBRT) may be an effective way to cure men of early-stage prostate cancer with fewer side effects than standard treatments. Objective: To see how people with untreated localized prostate cancer will respond to focal therapy with SBRT. Eligibility: People aged 18 years and older with untreated localized prostate cancer (prostate cancer which has not spread outside of the prostate gland). Design: * Participants will undergo screening including blood tests, an MRI, a PSMA PET/CT (18F-DCFPyL), and a biopsy. * Small, non-radioactive, gold seeds about the size of a grain of rice will be placed in and/or around the tumor to help target the radiation treatment. * Radiation (SBRT) will occur in 2 separate sessions about 1 week apart. No sedation is used, these sessions are painless. Each session will take about 1-2 hours. Participants can go home afterwards. * Follow-up will continue for 2 years with repeat scans (MRI and PSMA PET/CT) and blood (PSA) tests. * After two years, a biopsy will be done to understand the impact of this new treatment on prostate cancer.

Gender: MALE

Ages: 18 Years - 120 Years

Updated: 2026-11-20

1 state

Prostatic Neoplasms
Prostate Cancer
Prostate Adenocarcinoma
RECRUITING

NCT07830212

Diagnostic Performance of ACP3-Targeted PET Imaging in Patients With Primary and Recurrent Prostate Cancer: An Open-Label, Single-Arm, Single-Center Study

This study aims to evaluate the diagnostic performance of \[68Ga\]Ga-OncoACP3 PET imaging, which targets prostate acid phosphatase (ACP3), in men with clinically suspected or confirmed high-risk prostate cancer, or suspected recurrence after treatment. The study will assess the ability of this imaging to detect lesions and its diagnostic performance, including sensitivity, specificity, and accuracy. Histopathology and/or clinical follow-up of at least 6 months will be used as the reference standard. Participants will receive a single intravenous injection of \[68Ga\]Ga-OncoACP3 and undergo a PET/CT scan about 1 hour later. For participants who have already undergone clinically routine PSMA PET imaging, a comparison between the two imaging modalities will be performed. The study will enroll 50 men aged 18 to 90 years. Additionally, the study will explore the correlation between semi-quantitative parameters derived from \[68Ga\]Ga-OncoACP3 PET imaging and pathological markers (ACP3 expression assessed by immunohistochemistry in tumor tissue), and will evaluate the impact of \[68Ga\]Ga-OncoACP3 PET imaging on clinical treatment decisions.

Gender: MALE

Ages: 18 Years - 90 Years

Updated: 2026-11-18

1 state

Prostatic Neoplasms
Prostate Cancer
ACTIVE NOT RECRUITING

NCT01946204

A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer

The purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men with high-risk non-metastatic castration-resistant prostate cancer.

Gender: MALE

Ages: 18 Years - Any

Updated: 2026-11-17

43 states

Prostatic Neoplasms
ACTIVE NOT RECRUITING

NCT07936175

Pathological Micro-Niches and Multimodal Imaging Macro-Niches for Predicting Clinically Significant Prostate Cancer and Metastasis: A Multicenter Study

This is an investigator-initiated, multicenter, observational ambispective cohort study, predominantly retrospective, with an optional prospective non-interventional silent validation. The study tests a cross-scale hypothesis that the pathological micro-niche of the primary prostate tumor (tumor epithelium, invasive front, immune-rich or immune-poor regions, ECM/collagen remodeling, neurovascular neighborhoods, and peritumoral field effect) is associated at the patient level with the imaging macro-niche captured by multiparametric MRI (diffusion, perfusion, heterogeneity, local invasion) and PSMA PET/CT (receptor expression, whole-body lesion distribution, tumor burden). A pathology teacher model provides patient- or lesion-set-level niche representations only during model development; at deployment and validation, only MRI, PSMA PET/CT, and clinical information available before the prediction time point are used, with no voxel-level pathology-to-imaging registration. Under one master protocol with three pre-specified substudies, the system predicts: (A) patient- and lesion-level clinically significant prostate cancer (csPCa, ISUP Grade Group 2 or higher) from pre-biopsy MRI; (B) pathological pelvic lymph node metastasis (pN1) after radical prostatectomy with pelvic lymph node dissection, primarily from MRI; and (C) concurrent distant metastasis (M1) and subsequent distant metastasis in baseline M0 patients, primarily from PSMA PET/CT. Models are evaluated for discrimination, calibration, clinical net benefit, uncertainty, abstention, and stability across centers, scanners, tracers, and disease spectra, using locked multicenter external validation and prospective silent validation. Model outputs are never shown to clinicians or patients and do not alter care.

Gender: MALE

Ages: 18 Years - Any

Updated: 2026-11-13

1 state

Prostate Cancer
Prostatic Neoplasms
RECRUITING

NCT00923221

Collection of Blood From Patients With Prostate Cancer

Background: * It is not fully understood why prostate cancer in some men becomes androgen-independent (no longer responds to anti-androgen medication), but genetics likely plays an important role. * Genes contain the hereditary information that is passed down from parents to children. Although everyone has the same set of genes, individuals can have different forms of the same gene. * Differences in genes may explain, at least in part, why some people develop a more aggressive form of prostate cancer than others. Objectives: -To obtain blood samples from patients with prostate cancer to try to identify gene differences associated with progression to the androgen independent state. Eligibility: -All participants participating in NCI prostate cancer protocols. Design: * Participants with prostate cancer are evaluated in the NCI s Medical Oncology Clinic. * Blood samples are collected at the initial visit or at follow-up visits. * DNA (genetic material) and white blood cells are extracted from these samples to be used for genotyping and establishment of cell lines. * Gene variations are correlated with prostate cancer prognosis and prognostic indicators.

Gender: MALE

Ages: 18 Years - Any

Updated: 2026-11-12

1 state

Cancer Of Prostate
Prostate Cancer
Prostatic Neoplasms
+2
RECRUITING

NCT01834001

Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy

Background: \- Radiation is a common treatment for prostate cancer. It helps damage tumor cells and causes them to die. Radiation can be effective, but some tumors may be harder to treat with radiation or even with surgery. This happens to a small number of men who have either radiation or surgery for prostate cancer. Most men who have these hard-to-treat tumors do not know if the tumor has recurred only in the prostate or has spread to another area. Also, men whose prostate cancer has recurred only after radiation may have different treatment options. This study will use improved imaging studies to better understand why some men do not respond as well to initial radiation treatments. Objectives: \- To use detailed imaging studies to look at the results of local radiation therapy for prostate cancer. Eligibility: * Men at least 18 years of age who are scheduled to have radiation for prostate cancer. * Men at least 18 years of age whose prostate cancer has returned after earlier treatments. Design: * All participants will have a medical history and physical exam. Blood and urine samples will be collected. Imaging studies will be used to evaluate the cancer at the start of the study. * All participants will have an initial full magnetic resonance imaging (MRI) scan of the prostate. Tumor and healthy tissue samples will be collected. * Those whose cancer has recurred after treatment will discuss possible treatment options with the study doctors. * Participants who are scheduled to have radiation will have radiation therapy. This will be given according to the current standard of treatment. * After radiation, participants will have regular follow-up tests and imaging studies. They will have another full MRI scan 6 months after the end of radiation treatment.

Gender: MALE

Ages: 18 Years - 120 Years

Updated: 2026-11-12

1 state

Prostatic Neoplasms
Prostate Cancer
TERMINATED

NCT07406282

A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics

Prostate cancer is the most common non-skin cancer among men in the United States. For some men, the cancer has already spread to other parts of the body at the time of diagnosis; this is called metastatic hormone-sensitive prostate cancer (mHSPC). Treatment for mHSPC has advanced significantly, with new standards of care involving androgen deprivation therapy (ADT) combined with drugs known as androgen receptor pathway inhibitors (ARPIs), sometimes alongside chemotherapy like docetaxel. Darolutamide is an ARPI that is approved by the FDA for treating mHSPC in a "triplet" combination with ADT and docetaxel. It is also used in a "doublet" combination with ADT alone. However, there is limited information on how darolutamide is used in real-world clinical settings for this condition, which creates a gap in knowledge for making treatment decisions. This study aims to fill that gap by analyzing real-world data from electronic medical records. The primary goal is to describe the characteristics of patients with newly diagnosed mHSPC who are treated with darolutamide (either as a doublet or triplet) in urology clinics across the US. The study will also examine drug use patterns and clinical outcomes for these patients. Additionally, the study will explore the characteristics of patients treated with other ARPIs (abiraterone acetate, enzalutamide, and apalutamide) and assess the feasibility of creating matched patient groups for future comparative research. Data will be collected retrospectively from a large network of community urology practices in the US.

Gender: MALE

Ages: 18 Years - Any

Updated: 2026-11-10

1 state

Prostatic Neoplasms
Metastatic Hormone-Sensitive Prostate Cancer
RECRUITING

NCT06914427

PET/CT Imaging Study With Simultaneous Dual-nuclide Imaging Technique

This is a study using a self-control approach and is expected to recruit 35 volunteers, including prostate cancer patients, neuroendocrine tumour patients, glioma patients, lung cancer patients, and normal volunteers, to undergo dual-tracer PET/CT imaging and to validate the separation performance and quantitative accuracy of simultaneous dual-tracer imaging in humans.

Gender: All

Ages: 18 Years - 75 Years

Updated: 2026-11-10

1 state

Prostatic Neoplasms
Glioma
Lung Cancer
+1
ACTIVE NOT RECRUITING

NCT07918235

Spatial Needle Placement Strategies and Pathological Concordance in Prostate Biopsy: A National Multicenter Retrospective Cohort Study

Prostate cancer is a major malignancy in men, and prostate biopsy determines both cancer detection and risk stratification. Biopsy strategies vary substantially across centers in approach (transperineal vs. transrectal), use of multiparametric MRI (mpMRI), targeted versus systematic sampling, and the spatial distribution of cores; however, most prior databases record only the total number of cores and cannot reconstruct the spatial location of individual cores. This national multicenter, retrospective, non-interventional observational cohort study, led by Guangxi Medical University and involving more than 20 hospitals across more than 10 provinces in China, will establish a layered database linking patients, MRI lesions, biopsy events, actual needle passes/specimen jars/cores, and radical prostatectomy pathology, and will convert historical needle-placement strategies into unified, auditable spatial variables. The study aims to compare the detection rate and per-core detection efficiency of ISUP Grade Group (GG) \>=2 prostate cancer across different spatial needle-placement strategies, to estimate the absolute missed-cancer cost and core-saving benefit of candidate reduced templates through within-patient reconstruction, and to evaluate the concordance, upgrading, and downgrading between biopsy and radical prostatectomy GG. The study adds no tests, biopsies, treatment, or follow-up, and the main risks are privacy breach and data misuse. Target enrollment is at least 30,000 cases.

Gender: MALE

Ages: 18 Years - Any

Updated: 2026-11-05

1 state

Prostate Cancer
Prostatic Neoplasms
ACTIVE NOT RECRUITING

NCT04497844

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)

The purpose of the study is to determine if the combination of niraparib with Abiraterone Acetate (AA) plus prednisone compared with AA plus prednisone in participants with deleterious germline or somatic Homologous Recombination Repair (HRR) gene-mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) provides superior efficacy in improving radiographic progression-free survival (rPFS).

Gender: MALE

Ages: 18 Years - Any

Updated: 2026-11-04

27 states

Prostatic Neoplasms
COMPLETED

NCT04689828

177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

The purpose of this study is to determine whether 177Lu-PSMA-617 improves the Radiographic progression-free survival (rPFS) or Overall Survival (OS) compared to a change in Androgen receptor-directed therapy (ARDT) in metastatic castrate resistant prostate cancer (mCRPC) participants that were previously treated with an alternate ARDT and not exposed to a taxane-containing regimen in the CRPC or mHSPC settings. 469 participants were randomized (235 in the 177Lu-PSMA-617 group and 234 in the ARDT group.

Gender: MALE

Ages: 18 Years - 100 Years

Updated: 2026-11-04

27 states

Prostatic Neoplasms
ACTIVE NOT RECRUITING

NCT02257736

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

The purpose of this study is to compare the radiographic progression-free survival (rPFS) of apalutamide in combination with abiraterone acetate (AA) plus prednisone or prednisolone (AAP) and AAP in participants with chemotherapy-naive (participants who did not receive any chemotherapy \[treatment of cancer using drugs\]) metastatic castration-resistant prostate cancer (mCRPC) (cancer of prostate gland \[gland that makes fluid that aids movement of sperm\]).

Gender: MALE

Ages: 18 Years - Any

Updated: 2026-11-04

26 states

Prostatic Neoplasms
ACTIVE NOT RECRUITING

NCT04720157

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

The purpose of this study is to evaluate the efficacy and safety of 177Lu-PSMA-617 in combination with Standard of Care (SOC), versus Standard of Care alone, in adult male patients with Metastatic hormone sensitive prostate cancer (mHSPC). In this study, the SoC is defined as a combination of Androgen Receptor Directed Therapy (ARDT) + Androgen Deprivation Therapy (ADT). Approximately 1126 patients will be randomized in this study. As of 31-Jan-2024, 1144 participants were enrolled in 19 countries.

Gender: MALE

Ages: 18 Years - 100 Years

Updated: 2026-11-04

52 states

Prostatic Neoplasms
COMPLETED

NCT01913106

HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

The purpose of this study is to conduct a Phase I - II clinical trial to extend preclinical studies involving in situ HSV-tk + Valacyclovir gene therapy in combination with brachytherapy for recurrent prostate cancer. This will provide a novel therapeutic approach to prostate cancer and hopefully impact on the development of metastatic disease and the control of preexisting metastasis.

Gender: MALE

Ages: 18 Years - Any

Updated: 2026-11-04

1 state

Prostatic Neoplasms
RECRUITING

NCT07832292

A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer

The purpose of this study is to evaluate how well JNJ-101556143 works in participants with metastatic androgen pathway modulation-resistant prostate cancer (mAPMR), an advanced form of prostate cancer that has spread and no longer responds to hormone therapy. The study will measure the overall response (tumor shrinkage or disappearance) following treatment with JNJ-101556143.

Gender: MALE

Ages: 18 Years - Any

Updated: 2026-11-03

7 states

Prostatic Neoplasms
ACTIVE NOT RECRUITING

NCT03173924

18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer

Background: Prostate cancer is the second leading cause of cancer deaths in American men. Few options exist to create images of this type of cancer. Researchers think an experimental radiotracer called 18F-DCFPyL could find sites of cancer in the body. Objective: To see if 18F-DCFPyL can identify sites of prostate cancer in people with the disease. Eligibility: People ages 18 and older who have metastatic prostate cancer Design: Participants will be screened with: * Blood tests * Physical exam * Medical history Participants will be assigned to 1 of 2 groups based on their PSA. Participants will have 18F-DCFPyL injected into a vein. About 2 hours later they will have a whole-body Positron Emission Tomography/Computed Tomography (PET/CT). For the scan, they will lie on their back on the scanner table while it takes pictures of the body. This lasts about 50 minutes. On another day, participants will have 18F -NaF injected into a vein. About 1 hour later, they will have a whole-body PET/CT. Participants will be contacted 1 3 days later for follow-up. They may undergo PET/Magnetic Resonance Imaging (MRI) either after having a 18F-DCFPyL PET/CT, or in place of PET/CT imaging. A tube may be placed in the rectum. More coils may be wrapped around the outside of the pelvis. If the 18F-DCFPyL PET/CT is positive participants will be encouraged to undergo a biopsy of one of the tumors. The biopsy will be taken through a needle put through the skin into the tumor. Participants will be followed for 1 year. During this time researchers will collect information about their prostate cancer, such as PSA levels and biopsy results. About 4-6 months after scanning is completed, participants may have a tumor biopsy. The biopsy will be taken through a needle put through the skin into the tumor. ...

Gender: MALE

Ages: 18 Years - Any

Updated: 2026-11-03

1 state

Metastatic Prostate Cancer
Prostatic Neoplasms
Prostate Cancer
+2
ACTIVE NOT RECRUITING

NCT03523442

A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer

The purpose of this study is to evaluate pharmacokinetics (PK) following a single dose and multiple dose treatment and the safety of apalutamide in Chinese participants with metastatic castration resistant prostate cancer (mCRPC) at dose of 240 milligram (mg).

Gender: MALE

Ages: 18 Years - Any

Updated: 2026-11-03

Prostatic Neoplasms
ACTIVE NOT RECRUITING

NCT02123758

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

The purpose of this study is to investigate potential drug-drug interaction (DDI) between JNJ-56021927 and abiraterone acetate and between JNJ-56021927 and prednisone, determine safety of the combination and evaluate in a descriptive manner the efficacy in these participants. It will also, potentially provide dosing recommendations for abiraterone acetate in future studies when combined with JNJ-56021927.

Gender: MALE

Ages: 18 Years - 99 Years

Updated: 2026-11-03

4 states

Prostatic Neoplasms
Metastatic Castration-Resistant Prostate Cancer
ACTIVE NOT RECRUITING

NCT04577833

A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer

The purpose of this study is to determine the relative bioavailability (rBA; Period 1) and bioequivalence (BE; Period 2 and 3) of various strengths and formulations of niraparib and abiraterone acetate (AA) at steady state under modified fasted conditions in participants with metastatic castration-resistant prostate cancer (mCRPC).

Gender: MALE

Ages: 18 Years - Any

Updated: 2026-11-03

1 state

Prostatic Neoplasms
ACTIVE NOT RECRUITING

NCT04557059

A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer

The main purpose of this study is to determine if the addition of apalutamide to radiotherapy (RT) plus luteinizing hormone-releasing hormone agonist (LHRHa) delays metastatic progression as assessed by prostate specific membrane antigen-positron emission tomography (PSMA-PET) or death compared with RT plus LHRHa alone.

Gender: MALE

Ages: 18 Years - Any

Updated: 2026-11-03

12 states

Prostatic Neoplasms
RECRUITING

NCT07746713

A Study of JNJ-98768111 in Participants With Advanced Prostate Cancer

The purpose of Part 1 of this study is to find out how safe JNJ-98768111 is and the most suitable dose (recommended phase 2 dose \[RP2D\]) regimen(s) of JNJ-98768111. The purpose of Part 2 of this study is to find out how safe JNJ-98768111 is at the RP2D regimen(s) in participants with advanced prostate cancer (cancer of the prostate, a male reproductive gland found below the bladder, which has spread extensively to other parts of the body).

Gender: MALE

Ages: 18 Years - Any

Updated: 2026-11-03

4 states

Prostatic Neoplasms
ACTIVE NOT RECRUITING

NCT04644770

A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) of JNJ-69086420 in Part 1 (Dose Escalation), to determine safety and preliminary signs of clinical activity at the RP2D(s) in Part 2 (Dose Expansion), to determine safety of JNJ-69086420 at the RP2D(s) as a combination therapy in Part 3 (combination therapy) and to determine safety of JNJ-69086420 at the RP2D(s) in participants with metastatic hormone-sensitive prostate cancer (mHSPC) in Part 4.

Gender: MALE

Ages: 18 Years - Any

Updated: 2026-11-03

10 states

Prostatic Neoplasms
Adenocarcinoma
ACTIVE NOT RECRUITING

NCT02531516

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

The purpose of this study is to determine if apalutamide plus gonadotropin releasing hormone (GnRH) agonist in participants with high-risk, localized or locally advanced prostate cancer receiving primary radiation therapy (RT) results in an improvement of metastasis-free survival (MFS) based on conventional imaging assessed by blinded independent central review (BICR).

Gender: MALE

Ages: 18 Years - Any

Updated: 2026-11-03

32 states

Prostatic Neoplasms